
Sign up to save your podcasts
Or


This week’s episode will be focusing on one of the GI plenary session abstracts presented at the ASCO Annual Meeting 2025, the MATTERHORN trial: phase 3 durvalumab + FLOT which is 5FU leucovorin, oxaliplatin and docetaxel in resectable gastric or GE junction CA.
By Sam and Karine4.8
193193 ratings
This week’s episode will be focusing on one of the GI plenary session abstracts presented at the ASCO Annual Meeting 2025, the MATTERHORN trial: phase 3 durvalumab + FLOT which is 5FU leucovorin, oxaliplatin and docetaxel in resectable gastric or GE junction CA.

319 Listeners

506 Listeners

40 Listeners

122 Listeners

57 Listeners

3,360 Listeners

1,152 Listeners

188 Listeners

47 Listeners

517 Listeners

373 Listeners

51 Listeners

59 Listeners

51 Listeners

46 Listeners